Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68788-7891

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68788-7891). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
This appears to be a list of drugs and their interactions, followed by some PK (pharmacokinetic) information and recommendations for use. There is also a list of "analytes" or substances being measured, including veristaxine, and some numerical data. However, the output contains many errors and typos, making it difficult to interpret.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
This appears to be a combination of drug names and some analytical results, but the text is not well-formatted, and some of the words appear to be errors. Therefore, it is not clear what information is being conveyed or what the context is. Hence, the description cannot be generated.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
This text provides recommendations for dosage adjustments of Enlafaxine based on various medical conditions such as hepatic impairment, renal impairment, age, and gender. For instance, when the patient has mild to moderate hepatic impairment or renal impairment, the dosage of Enlafaxine should be lowered by 50% or greater, and individualization of dosing may be necessary. The text also indicates that no dose adjustment is required for CYP2D6 polymorphism, age (>60 years), and gender (females/males). Additionally, the text provides a graph showing the change relative to the reference value for Special Populatidmalyte PK Fold Change and 90% Cl, plotted against time.*
FDA Label Image

Logo1 (Logo1)

FDA Label Image

Logo2 (Logo2)

FDA Label Image

Venlafaxine HCl Extended-release Capsules 37.5mg (Venlafaxine Hydrochloride 30 Capsules)

Venlafaxine HCl Extended-release Capsules 37.5mg (Venlafaxine Hydrochloride 30 Capsules)
This is a medication description for Venlafaxine HCI extended-release capsules in 37.5mg dose, which is the generic version of Effexor ER. The capsules are manufactured by Camber Pharmaceuticals and are meant to be taken in intervals of every few hours. The packaging includes cautionary instructions against transferring the capsules to anyone other than the patient they are intended for. There are also product and lot numbers listed on the packaging.*
FDA Label Image

Venlafaxinestructure (Venlafaxinestructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.